5GH Stock Overview
A precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Guardant Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$29.44 |
| 52 Week High | US$33.82 |
| 52 Week Low | US$15.02 |
| Beta | 1.11 |
| 11 Month Change | 58.07% |
| 3 Month Change | 17.90% |
| 1 Year Change | 38.87% |
| 33 Year Change | -68.89% |
| 5 Year Change | n/a |
| Change since IPO | -68.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5GH | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 4.1% | 0.1% | -0.02% |
| 1Y | 38.9% | 17.2% | 8.2% |
Return vs Industry: 5GH exceeded the German Healthcare industry which returned 15.7% over the past year.
Return vs Market: 5GH exceeded the German Market which returned 7.4% over the past year.
Price Volatility
| 5GH volatility | |
|---|---|
| 5GH Average Weekly Movement | 8.4% |
| Healthcare Industry Average Movement | 4.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5GH's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 5GH's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 1,774 | Helmy Eltoukhy | guardanthealth.com |
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection.
Guardant Health, Inc. Fundamentals Summary
| 5GH fundamental statistics | |
|---|---|
| Market cap | €3.68b |
| Earnings (TTM) | -€492.07m |
| Revenue (TTM) | €664.77m |
5.8x
P/S Ratio-7.9x
P/E RatioIs 5GH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5GH income statement (TTM) | |
|---|---|
| Revenue | US$692.26m |
| Cost of Revenue | US$274.72m |
| Gross Profit | US$417.53m |
| Other Expenses | US$929.94m |
| Earnings | -US$512.41m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.15 |
| Gross Margin | 60.31% |
| Net Profit Margin | -74.02% |
| Debt/Equity Ratio | -1,900.1% |
How did 5GH perform over the long term?
See historical performance and comparison